文献速递胃肠外科围术期管理与 ERAS

内镜袖状胃成形术与腹腔镜袖状胃切除术6个月结局对比:MBSAQIP分析

Six-month comparative outcomes of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: an MBSAQIP analysis.
PubMed 文献 · Surg Endosc · 2026-10-15

基于MBSAQIP 2023数据库及6个月随访数据,比较择期内镜袖状胃成形术(ESG)与腹腔镜袖状胃切除术(LSG)的安全性和疗效。共纳入115,476例患者(LSG 114,967例,ESG 509例)。6个月时LSG减重效果更优,且代谢合并症改善明显,而ESG未见有临床意义的合并症改善。

要点

  • LSG 6个月减重优于ESG:BMI减少8.2 vs 3.9 kg/m²,总体重减少22.6 vs 11.1 kg。
  • LSG后药物/胰岛素依赖型糖尿病近50%缓解,血脂异常、高血压、睡眠呼吸暂停均改善。
  • ESG后6个月无有临床意义的合并症改善,尽管基线合并症更少。

核心结论

  • 与ESG相比,LSG在6个月时提供更大的总体重减轻、更短手术时间,并伴随显著的代谢合并症改善。
  • ESG患者在6个月时未见有临床意义的合并症缓解。

研究设计与样本

  • 回顾性队列研究,数据来自MBSAQIP 2023数据库并合并6个月随访文件。
  • 共纳入115,476例患者,其中LSG 114,967例,ESG 509例。

主要发现

  • ESG患者年龄稍大(44.5±11.2 vs 42.4±11.9岁,p=0.0001),基线BMI更低(40.9±8.6 vs 45.0±7.8 kg/m²,p<0.0001),平均体重更低(113.2±28 vs 124.5±26.3 kg)。
  • 6个月时LSG的BMI减少更大(8.2±10.8 vs 3.9±12.0 kg/m²,p<0.0001),总体重减少更大(22.6±35.6 vs 11.1±37.7 kg,p<0.0001)。
  • LSG后药物/胰岛素依赖型糖尿病近50%减少,血脂异常、高血压和睡眠呼吸暂停率改善。
  • ESG后从基线至6个月未见有临床意义的合并症改善。

临床怎么用

  • 在 accredited MBSAQIP 中心,LSG在6个月减重和代谢合并症改善方面优于ESG。
  • ESG在6个月内未显示有临床意义的代谢合并症缓解,选择时需考虑此短期局限。

局限性

  • ESG样本量较小(509例),可能影响统计效力。
  • 随访仅6个月,无法评估长期疗效和耐久性。
  • ESG组基线合并症较少,可能影响合并症改善的比较。
  • 为回顾性数据库分析,存在选择偏倚和未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: North American data regarding long-term efficacy and durability of endoscopic sleeve gastroplasty (ESG) are remarkably scarce outside of clinical trial settings hampering our understanding of its optimal role in the obesity care continuum. The aims of this study are to compare safety and efficacy of elective ESG versus laparoscopic sleeve gastrectomy (LSG) at 6 months using accredited MBSAQIP centers. METHODS: Data were obtained from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database for 2023 and merged with the 6‑month follow‑up data file. The primary objectives of the study were to characterize the long-term six-month changes in weight and metabolic comorbidities of ESG patients in contrast to their LSG counterparts. Logistic regression models were to evaluate for differences in six-month serious complications and emergency department readmissions between ESG and LSG. RESULTS: A total of 115,476 patients were included, comprising 114,967 LSG and 509 ESG procedures. Patients undergoing ESG were slightly older (44.5 ± 11.2 vs. 42.4 ± 11.9 years, p = 0.0001) and had lower baseline BMI (40.9 ± 8.6 vs. 45.0 ± 7.8 kg/m2, p < 0.0001) and mean body weight (113.2 ± 28 vs. 124.5 ± 26.3 kg). At 6 months, LSG resulted in greater weight reduction, with larger BMI loss (8.2 ± 10.8 vs. 3.9 ± 12.0 kg/m2, p < 0.0001), and total weight loss (22.6 ± 35.6 vs. 11.1 ± 37.7 kg, p < 0.0001). For patients undergoing LSG, there was a near 50% reduction in medication/insulin-dependent diabetes along with improvements in rates of dyslipidemia, hypertension, and sleep apnea. Importantly, no clinically meaningful comorbidity improvements from baseline to 6 months were seen following ESG. CONCLUSION: When compared to ESG at 6 months, LSG provides an improvement in total body weight loss, has a reduced operative time, and is associated with dramatic metabolic comorbidity improvement including a reduction in resolution of medication and insulin-dependent diabetes. No clinically meaningful comorbidity resolution was seen in patients receiving ESG compared to LSG at 6 months although this cohort was less comorbid at baseline.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Mocanu V, Wills MV, Zhu X, et al. Six-month comparative outcomes of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: an MBSAQIP analysis. Surg Endosc. 2026. PMID: 42881311. doi:10.1007/s00464-026-13489-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。